# A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder

> **NCT03107026** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 491 (actual)

## Conditions studied

- Binge Eating Disorder

## Interventions

- **DRUG:** dasotraline 4mg
- **DRUG:** dasotraline 6mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03107026
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-31
- **Primary completion:** 2018-05-16
- **Final completion:** 2018-05-16
- **Target enrollment:** 491 (ACTUAL)
- **Last updated:** 2020-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03107026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03107026, "A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03107026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*